Compare Datadog Inc (DDOG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Datadog Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Datadog Inc trades at $291.75 (market cap $98.31B), while State Street SPDR S&P Biotech ETF trades at $153.78 (market cap $10.11B). The key difference: Datadog Inc is far larger — about 9.7× State Street SPDR S&P Biotech ETF's market cap, and Datadog Inc is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Datadog Inc for 76 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| DDOG | XBI | |
|---|---|---|
Market Cap | $98.31B | $10.11B |
Volume | 2,936,660 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $288.15 | $169.55 |
52-Week Low | $102.62 | $104.99 |
Typical Hold Time | 76 Days | 38 Days |
Enterprise Value | $94.61B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Datadog (DDOG) trades at $290.26, up 6.97% with strong bullish momentum approaching 52-week highs. The stock shows robust revenue growth reaching $3.43B in 2025, though profitability metrics remain mixed with a high P/E ratio of 547.6. Recent earnings beats and accelerating enterprise customer expansion support positive sentiment, while technical indicators show the stock trading near resistance at $288 with strong moving average support.
Investment outlook remains positive given strong analyst consensus (83% buy ratings) and AI-driven growth catalysts, though elevated valuation and negative cash flow trends present risks. The $276.10 consensus price target suggests limited upside from current levels, requiring continued execution on enterprise expansion and margin improvement to justify premium valuation.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Datadog Inc
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
